أستونيا - الإستونية - Ravimiamet

mcdermott laboratories limited t/a gerard laboratories - levofloksatsiin - kaetud tablett - 500mg 10tk

أستونيا - الإستونية - Ravimiamet

laboratorio farmaceutico c.t. s.r.l. - kaltsitriool - pehmekapsel - 0,25mcg 30tk

أستونيا - الإستونية - Ravimiamet

mylan hungary kft. - frovatriptaan - kaetud tablett - 2,5mg 6tk

أستونيا - الإستونية - Ravimiamet

viatris limited - dabigatraaneteksilaat - kõvakapsel - 75mg 30tk

أستونيا - الإستونية - Ravimiamet

mylan laboratories sas - beetahistiin - tablett - 16mg 100tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

viatris limited - klopidogreel-besilaat - peripheral vascular diseases; stroke; myocardial infarction - antitrombootilised ained - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmendi elevatsiooniga ägeda müokardi infarkti korral kombinatsioonis asa on meditsiiniliselt ravitud patsientide abikõlblikud trombolüütiline ravi. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. täiendava teabe jaoks vt osa 5.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

viatris healthcare limited - tobramycin - cystic fibrosis; respiratory tract infections - antibacterials süsteemseks kasutamiseks, - tobi podhaler on näidustatud kroonilise pulmonaalse infektsiooni tõttu fibroosiga täiskasvanutel ja 6-aastastel lastel pärssivat ravi tsüstilise fibroosiga. vt lõigud 4. 4 ja 5. 1 andmete kohta erinevates vanuserühmades. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

أستونيا - الإستونية - Ravimiamet

viatris limited - dabigatraaneteksilaat - kõvakapsel - 150mg 30tk; 150mg 100tk; 150mg 180tk

أستونيا - الإستونية - Ravimiamet

viatris limited - tikagreloor - õhukese polümeerikattega tablett - 90mg 100tk; 90mg 60tk; 90mg 30tk; 90mg 168tk; 90mg 180tk

أستونيا - الإستونية - Ravimiamet

viatris limited - pemetrekseed - infusioonilahuse kontsentraat - 25mg 1ml 40ml 1tk; 25mg 1ml 4ml 1tk; 25mg 1ml 20ml 1tk